A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells
Molecular Therapy · 2023
DOI: 10.1016/j.ymthe.2023.04.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von Peter J Cook und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunity and Immunotherapies and the Program for Cell and Gene Therapy, Seattle Children's Research Institute, 1900 Ninth Avenue, Seattle …. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Interleukin-2. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust, Seattle Children's Research Institute, Canadian Institute of Steel Construction.
Abstract (Originalsprache)
Engineered T cells represent an emerging therapeutic modality. However, complex engineering strategies can present a challenge for enriching and expanding therapeutic cells at clinical scale. In addition, lack of in vivo cytokine support can lead to poor engraftment of transferred T cells, including regulatory T cells (Treg). Here, we establish a cell-intrinsic selection system that leverages the dependency of primary T cells on IL-2 signaling. FRB-IL2RB and FKBP-IL2RG fusion proteins were identified permitting selective expansion of primary CD4+ T cells in rapamycin supplemented medium. This chemically inducible signaling complex (CISC) was subsequently incorporated into HDR donor templates designed to drive expression of the Treg master regulator FOXP3. Following editing of CD4+ T cells, CISC+ engineered Treg (CISC EngTreg) were selectively expanded using rapamycin and maintained Treg activity. Following transfer into immunodeficient mice treated with rapamycin, CISC EngTreg exhibited sustained engraftment in the absence of IL-2. Furthermore, in vivo CISC engagement increased the therapeutic activity of CISC EngTreg. Finally, an editing strategy targeting the TRAC locus permitted generation and selective enrichment of CISC+ functional CD19-CAR-T cells. Together, CISC provides a robust platform to achieve both in vitro enrichment and in vivo engraftment and activation, features likely beneficial across multiple gene-edited T cell applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immunity and Immunotherapies and the Program for Cell and Gene Therapy, Seattle Children's Research Institute, 1900 Ninth Avenue, Seattle WA 98101, USA.
- GentiBio, Inc., 150 Cambridgepark Drive, Cambridge, MA 02140, USA.
- Center for Immunity and Immunotherapies and the Program for Cell and Gene Therapy, Seattle Children's Research Institute, 1900 Ninth Avenue, Seattle WA 98101, USA; Department of Pediatrics, University of Washington, Sea…
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
- Seattle Children's Research Institute
- Canadian Institute of Steel Construction
- Akebia Therapeutics
Zitieren
APA
Cook, P. J., Yang, S. J., Uenishi, G. I., Grimm, A., West, S. E., Wang, L. J., Jacobs, C., Repele, A., Drow, T., Boukhris, A., Dahl, N. P., Sommer, K., Scharenberg, A. M., & Rawlings, D. J. (2023). A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.04.021
Vancouver
Cook PJ, Yang SJ, Uenishi GI, Grimm A, West SE, Wang LJ, et al. A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.04.021
BibTeX
@article{Cook2023,
author = {Cook, Peter J and Yang, Su Jung and Uenishi, Gene I and Grimm, Annaiz and West, Samuel E and Wang, Li-Jie and Jacobs, Chester and Repele, Andrea and Drow, Travis and Boukhris, Ahmad and Dahl, Noelle P and Sommer, Karen and Scharenberg, Andrew M and Rawlings, David J},
title = {A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells},
journal = {Molecular Therapy},
year = {2023},
doi = {10.1016/j.ymthe.2023.04.021}
}
EUVIMED